Account-creators
1,040
edits
Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
→IHC: update
Jensflorian (talk | contribs) (→Molecular: update) |
Jensflorian (talk | contribs) (→IHC: update) |
||
| Line 370: | Line 370: | ||
*PR +ve (approx. 75%, expression decreases from grade I to III). | *PR +ve (approx. 75%, expression decreases from grade I to III). | ||
*SSTR2A +ve (approx. 95%). | *SSTR2A +ve (approx. 95%). | ||
*S100 variable (up to 35% cases, usually patchy). | *S100 variable (up to 35% cases, usually patchy).<ref>{{cite journal |vauthors=Behling F, Fodi C, Skardelly M, Paulsen F, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J |title=The prognostic role of the immunohistochemical expression of S100 in meningiomas |journal=J Cancer Res Clin Oncol |volume= |issue= |pages= |date=July 2022 |pmid=35838837 |doi=10.1007/s00432-022-04186-9 |url=}}</ref> | ||
*SOX10 -ve. | *SOX10 -ve. | ||
*GFAP -ve. | *GFAP -ve. | ||
*CD34 usu. -ve (approx 8% cases positive). | *CD34 usu. -ve (approx 8% cases positive). | ||
*CD13 +ve.<ref>{{cite journal |vauthors=Marletta S, Luchini C, Sperandio N, Torresani E, Sorio A, Girolami I, Scarpa A, Eccher A, Ghimenton C |title=CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications |journal=Virchows Arch |volume=480 |issue=6 |pages=1223–1230 |date=June 2022 |pmid=35212813 |pmc=9184408 |doi=10.1007/s00428-022-03304-9 |url=}}</ref> | |||
*Other CKs usually -ve (approx 6% cases positive, mostly secretory meningiomas). | *Other CKs usually -ve (approx 6% cases positive, mostly secretory meningiomas). | ||